Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
We have undergone significant changes to our business and operations as a result of a series of completed transactions summarized below and discussed in further detail under the next section titled Recent Developments below. As a result of these transactions, we have significantly reduced our legacy pharmaceutical business operations and have adopted a new strategic direction as a busi…
Negative free cash flow of -$8M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$631M
▼ -8632.9% YoY
Op. Margin
—
ROIC
—
Cash Flow & Balance Sheet
FCF (TTM)
-$8M
▼ -12.4% YoY
Op. Cash Flow (TTM)
-$8M
▼ -12.4% YoY
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$8M
5Y CAGR: +8.2%
Continue Research